Enhanced Antitumor Effect of Curcumin Liposomes with Local Hyperthermia in the LL/2 Model |
Tang, Jian-Cai
(State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Shi, Hua-Shan (State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) Wan, Li-Qiang (State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) Wang, Yong-Sheng (Department of Thoracic Oncology, West China Hospital, West China Medical School, Sichuan University) Wei, Yu-Quan (State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) |
1 | Arbiser JL, Klauber N, Rohan R, et al (1998). Curcumin is an in vivo inhibitor of angiogenesis. Mol Med, 4, 376-78. |
2 | Bergers G, Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3, 401-10. DOI ScienceOn |
3 | Bhandarkar SS, Arbiser JL (2007). Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol, 595, 185-95. DOI |
4 | Bhattacharyya S, Hossain DMS, Mohanty S, et al (2010). Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol, 7, 306-15. DOI ScienceOn |
5 | Bhattacharyya S, Mandal D, Saha B, et al (2007). Curcumin prevents tumor-induced T cell apoptosis through Stat-5amediated Bcl-2 induction. J Biol Chem, 282, 15954-64. DOI ScienceOn |
6 | Calderwood SK, Theriault JR, Gong J (2005). Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol, 35, 2518-27. DOI ScienceOn |
7 | Chen P, Yang L, Yang H, et al (2008). Synergistic antitumor effect of CXCL10 with hyperthermia. J Cancer Res Clin, 134, 679-87. DOI |
8 | Cheng AL, Hsu CH, Lin JK, et al (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with highrisk or pre-malignant lesions. Anticancer Res, 21, 2895-990. |
9 | Dayanc BE, Beachy SH, Ostberg JR, et al (2008). Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Int J Hyperther, 24, 41-56. DOI ScienceOn |
10 | Dhillon N, Aggarwal BB, Newman RA, et al (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res, 14, 4491-9. DOI ScienceOn |
11 | Folkman J (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol, 3, 65-71 |
12 | Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8. |
13 | Gasparini G, Longo R, Toi M, et al (2005). Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol, 2, 562-77. |
14 | Goel A, Kunnumakkara AB, Aggarwal BB (2008). Curcumin as " Curecumin": From kitchen to clinic. Biochem Pharmacol, 75, 787-809. DOI ScienceOn |
15 | Granci V, Dupertuis YM, Pichard C (2010). Angiogenesis as a potential target of pharmaconutrients in cancer therapy. Curr Opin Clin Nutr, 13, 417-22. DOI ScienceOn |
16 | Gururaj AE, Belakavadi M, Venkatesh DA, et al (2002). Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun, 297, 934-42. DOI ScienceOn |
17 | Hildebrandt B, Wust P, Ahlers O, et al (2002). The cellular and molecular basis of hyperthermia. Crit Rev Oncol, 43, 33-56. DOI ScienceOn |
18 | Huang Q, Hu JK, Lohr F, et al (2000). Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res, 60, 3435-39. |
19 | Karunagaran D, Rashmi R, Kumar T (2005). Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Tar, 5, 117-29. DOI ScienceOn |
20 | Liu JY, Wei YQ, Yang L, et al (2003). Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood, 102, 1815-23. DOI ScienceOn |
21 | Ma J, Chen CS, Blute T, Waxman DJ (2011). Antiangiogenesis enhances intratumoral drug retention. Cancer Res, 71, 2675-85. DOI |
22 | Manjili M, Wang XY, Park J, et al (2002). Cancer immunotherapy: stress proteins and hyperthermia. Int J Hyperther, 18, 506-20. DOI |
23 | Moyer HR, Delman KA (2008). The role of hyperthermia in optimizing tumor response to regional therapy. Int J Hyperther, 24, 251-61. DOI ScienceOn |
24 | Pajonk F, van Ophoven A, McBride WH (2005). Hyperthermiainduced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res, 65, 4836-43. DOI ScienceOn |
25 | Roca C, Primo L, Valdembri D, et al (2003). Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res, 63, 1500-07. |
26 | Sawaji Y, Sato T, Takeuchi A, et al (2002). Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro. Brit J Cancer, 86, 1597-603. DOI |
27 | Stankiewicz A, Livingstone A, Mohseni N, et al (2009). Regulation of heat-induced apoptosis by Mcl-1 degradation and its inhibition by Hsp70. Cell Death Differ, 16, 638-47. DOI ScienceOn |
28 | Wei YQ, Wang QR, Zhao X, et al (2000). Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med, 6, 1160-66. DOI ScienceOn |
29 | Zetter P, Bruce R (1998). Angiogenesis and tumor metastasis. Annu Rev Med, 49, 407-24. DOI ScienceOn |
30 | Zhang HG, Mehta K, Cohen P, et al (2008). Hyperthermia on immune regulation: a temperature's story. Cancer Lett, 271, 191-204. DOI ScienceOn |
![]() |